SEC Form 4 · accession 0001179110-16-033386

AMAG PHARMACEUTICALS INC. · AMAG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 20, 2016

Accepted (ET)

Dec 22, 2016 · 5:06 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000792977

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Dec 20, 2016	A	1,026	—	A	1,026	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2,F3	$35.50	Dec 20, 2016	A	6,000	A	—	Dec 20, 2026	Common Stock	6,000	6,000	D
Stock Option (Right to Buy)^F2,F4	$35.50	Dec 20, 2016	A	2,739	A	—	Dec 20, 2026	Common Stock	2,739	2,739	D

F1Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Third Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in five equal monthly installments commencing on January 1, 2017; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.
F2Not applicable.
F3Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant.
F4Grant of stock option pursuant to the Plan. This option will vest and become exercisable in five equal monthly installments commencing January 1, 2017.